Access to Medicine Index 2024 to Prioritise ‘Patient Reach’

While the 2022 Access to Medicine Index showed that the industry has made progress in widening the scale and scope of their access to medicine efforts in low- and middle-income countries, this progress remains uneven. To address this, the Methodology for the 2024 Index will place a greater focus on monitoring 'patient reach', aiming to get companies to be more standardised.

Iyer is quoted as saying: "“If the vision of the globe’s top industry executives is truly for every patient to have access to a drug, no matter their location or socioeconomic status, then this methodology will be extremely important. Companies need to embrace this methodology to understand whether their products are making it all the way to patients or not. Equity gaps will not be solved unless these organisations put their minds, hearts, staff, and infrastructure towards this important goal."

Read the Methodology for the 2024 Index here.